AGRX - Agile Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Show:
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
2022-12-31
2021-12-31
2020-12-31
2019-12-31
Total Revenue
10,884
10,884
4,101
749
0
Cost of Revenue
6,836
6,836
10,718
282
-
Gross Profit
4,048
4,048
-6,617
467
-
Operating Expenses
Research Development
3,253
3,253
6,246
13,500
9,858
Selling General and Administrative
42,229
42,229
58,142
36,020
9,000
Total Operating Expenses
45,482
45,482
64,388
49,520
18,858
Operating Income or Loss
-41,434
-41,434
-71,005
-49,053
-18,858
Interest Expense
3,131
3,131
3,914
3,109
0
Total Other Income/Expenses Net
14,398
14,398
-
-
-
Income Before Tax
-30,087
-30,087
-74,894
-51,853
-18,606
Income Tax Expense
-4,675
-4,675
-
0
0
Income from Continuing Operations
-25,412
-25,412
-74,894
-51,853
-18,606
Net Income
-25,412
-25,412
-74,894
-51,853
-18,606
Net Income available to common shareholders
-25,412
-25,412
-74,894
-51,853
-18,606
Basic EPS
-
-59.00
-1.54k
-1.22k
-760.00
Diluted EPS
-
-59.00
-1.54k
-1.22k
-760.00
Basic Average Shares
-
432.218
48.536
42.341
24.716
Diluted Average Shares
-
432.218
48.536
42.341
24.716
EBITDA
-
-26,956
-70,980
-48,744
-18,606